Osteogenic Mechanisms of Basal Ganglia Calcification and its ex vivo Model in the Hypoparathyroid Milieu

Endocrinology. 2021 Apr 1;162(4):bqab024. doi: 10.1210/endocr/bqab024.

Abstract

Context: Basal-ganglia calcification (BGC) is common (70%) in patients with chronic hypoparathyroidism. Interestingly, cortical gray matter is spared from calcification. The mechanism of BGC, role of hyperphosphatemia, and modulation of osteogenic molecules by parathyroid hormone (PTH) in its pathogenesis is not clear.

Objective: We assessed the expression of a large repertoire of molecules with proosteogenic or antiosteogenic effects, including neuroprogenitor cells in caudate, dentate, and cortical gray matter from normal autopsy tissues. The effect of high phosphate and PTH was assessed in an ex vivo model of BGC using striatum tissue culture of the Sprague-Dawley rat.

Methods: The messenger RNA and protein expression of 39 molecules involved in multiple osteogenic pathways were assessed in 25 autopsy tissues using reverse-transcriptase polymerase chain reaction, Western blot, and immunofluorescence. The striatal culture was maintained in a hypoparathyroid milieu for 24 days with and without (a) high phosphate (10-mm β-glycerophosphate) and (b) PTH(1-34) (50 ng/mL Dulbecco's modified Eagle's medium-F12 media) for their effect on striatal calcification and osteogenic molecules.

Results: Procalcification molecules (osteonectin, β-catenin, klotho, FZD4, NT5E, LRP5, WNT3A, collagen-1α, and SOX2-positive neuroprogenitor stem cells) had significantly higher expression in the caudate than gray matter. Caudate nuclei also had higher expression of antiosteogenic molecules (osteopontin, carbonic anhydrase-II [CA-II], MGP, sclerostin, ISG15, ENPP1, and USP18). In an ex vivo model, striatum culture showed an increased propensity for calcified nodules with mineral deposition similar to that of bone tissue on Fourier-transformed infrared spectroscopy, alizarin, and von Kossa stain. Mineralization in striatal culture was enhanced by high phosphate and decreased by exogenous PTH through increased expression of CA-II.

Conclusion: This study provides a conceptual advance on the molecular mechanisms of BGC and the possibility of PTH therapy to prevent this complication in a hypoparathyroid milieu.

Keywords: basal ganglia calcification; ex vivo model; hyperphosphatemia; hypoparathyroidism; osteogenic molecules.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Basal Ganglia / metabolism
  • Basal Ganglia / physiopathology*
  • Bone Morphogenetic Proteins / genetics
  • Bone Morphogenetic Proteins / metabolism
  • Calcinosis
  • Carbonic Anhydrases / genetics
  • Carbonic Anhydrases / metabolism
  • Caudate Nucleus / metabolism
  • Genetic Markers / genetics
  • Gray Matter / metabolism
  • Humans
  • Hypoparathyroidism / genetics
  • Hypoparathyroidism / metabolism
  • Hypoparathyroidism / physiopathology*
  • In Vitro Techniques
  • Male
  • Osteogenesis*
  • Osteonectin / genetics
  • Osteonectin / metabolism
  • Parathyroid Hormone / metabolism
  • Phosphates / metabolism
  • Phosphoric Diester Hydrolases / genetics
  • Phosphoric Diester Hydrolases / metabolism
  • Pyrophosphatases / genetics
  • Pyrophosphatases / metabolism
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Bone Morphogenetic Proteins
  • Genetic Markers
  • Osteonectin
  • Parathyroid Hormone
  • Phosphates
  • Sost protein, rat
  • Phosphoric Diester Hydrolases
  • ectonucleotide pyrophosphatase phosphodiesterase 1
  • Pyrophosphatases
  • Carbonic Anhydrases